Bio-Rad Launches SARS CoV-2 Standard For Coronavirus Testing
Zacks Investment Research | Mar 12, 2020 09:45PM ET
Bio-Rad Laboratories, Inc. (NYSE:BIO) announced the launch of SARS CoV-2 Standard to support the laboratory assay authentication of testing for coronavirus (COVID-19) as well as accelerate the access to testing. Notably, the SARS CoV-2 Standard was launched through the company’s Exact Diagnostics product line.
Notably, per the federal regulatory standards of the Clinical Laboratory Improvement Amendments (“CLIA”), it is mandatory for clinical laboratories to establish and document their performance specifications for laboratory-developed tests. This is to ensure the accuracy and preciseness of results before the test is implemented.
With the recent launch through the Exact Diagnostics product line, Bio-Rad aims to strengthen its Clinical Diagnostics business globally.
Significance of the Launch
Per the company, the launch of the SARS CoV-2 Standard is significant as it helps more laboratories to keep pace with the rising demand for coronavirus testing. During a public health emergency such as the current outbreak, Bio-Rad believes that it is imperative that more laboratories have access to well-defined standards for the validation of their tests.
Industry Prospects
Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.